Glioblastoma (IDH-WT, WHO grade 4) · line 1 · Temozolomide monotherapy

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	standard
Linked regimen	`REG-TMZ-MONO`

ID	`IND-GBM-NEWLY-DIAGNOSED-ELDERLY-TMZ`
Type	Indication
Status	reviewed 2026-05-04 \| pending_clinical_signoff
Diseases	`DIS-GBM`
Sources	`SRC-CCTG-CE6-PERRY-2017` `SRC-EANO-GBM-2024` `SRC-NCCN-CNS-2025` `SRC-NORDIC-GBM-MALMSTROM-2012`

Notes

For MGMT-methylated elderly GBM ≥70: TMZ alone is an alternative to hypofractionated RT + TMZ (CCTG CE.6). Choice based on tolerance for chemotherapy vs RT logistics. Both are NCCN category 1. REG-TMZ-MONO is temozolomide 150-200 mg/m²/d D1-5 q28d × 6 cycles. Note: palliative intent with best supportive care is always valid for patients with very poor PS (KPS <40, ECOG ≥4) or patient preference.

Used By

Algorithms

ALGO-GBM-NEWLY-DIAGNOSED-1L - ALGO-GBM-NEWLY-DIAGNOSED-1L